Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722668 · ClinicalTrials.gov registry record · Phase 2
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02722668 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 15 participants.
The verdict
NCT02722668, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Sirolimus
- DRUG MMF
- RADIATION TBI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2024-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722668
The ClinicalTrials.gov registry entry for NCT02722668 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02722668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02722668 about?
NCT02722668 is a clinical study titled "UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep". This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota ...
What is the current status of trial NCT02722668?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-05-15. Estimated completion is 2024-02-22.
What interventions are being tested in trial NCT02722668?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Sirolimus (DRUG), MMF (DRUG), TBI (RADIATION).
Who is sponsoring clinical trial NCT02722668?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.